United States of America
Bill Dawson retired from Eli Lilly and Co in 1996 after 27 years where he was Research Director for 14 years and took 15 compounds into development, two of which reached the market. Bill is currently a non-executive director of Proteome Sciences Plc, and Antitope Ltd as well as a member of a number of corporate Scientific Advisory Boards. He is Chairman of the Academy of Pharmaceutical Sciences and a Visiting Professor at the UCL School of Pharmacy. He is a member of the Expert Panel advising the Stevenage Bioscience Catalyst.